Immunohistochemical Expression of Cytokeratin 5/6 in Gynaecological Tumors.

Similar documents
Immunohistochemical Expression Of Cytokeratin 8 And 18 In Breast Carcinoma.

ACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION

Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases

WT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic Adenocarcinoma to Body Fluids

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Value of antimesothelioma HBME 1 in the diagnosis of inflammatory and malignant pleural effusions

ISSN X (Print) Original Research Article. DOI: /sjams

A Rare Case of Invasive Squamous Cell Carcinoma of Cervix Extending to Endometrium and Right Fallopian Tube

ROLE OF TTF-1, CK20, AND CK7 IMMUNOHISTOCHEMISTRY FOR DIAGNOSIS OF PRIMARY

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

CASE 4 21/07/2017. Ectopic Prostatic Tissue in Cervix. Female 31. LLETZ for borderline nuclear abnormalities

Histopathology: Cervical HPV and neoplasia

When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box?

Clinicopathological and Histological Features of Ovarian Tumour- A Study

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

Intravascular Endometrium Mimicking Vascular Invasion

Immunohistochemistry on Fluid Specimens: Technical Considerations

Gynaecological Malignancies

ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016

Histopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube

Olaf Kaufmann, MD, Ellen Fietze, MD, Jörg Mengs, and Manfred Dietel, MD. Abstract

Synonyms. Nephrogenic metaplasia Mesonephric adenoma

American Journal of. Medical Case Reports. CAM5.2 Expression in Metastatic Tumours of CNS: A Diagnostic Tool

Differentiation of Tumors with Specific Red Cell Adherence (SRCA) test

International Society of Gynecological Pathologists Symposium 2007

Neuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:

Nordic Immunohistochemical Quality Control

JMSCR Vol 3 Issue 9 Page September 2015

Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY

Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק

Int. J. Curr. Res. Med. Sci. (2017). 3(1): International Journal of Current Research in Medical Sciences

PREVALENCE OF GOBLET CELL METAPLASIA IN ENDOCERVICAL AND ENDOMETRIAL ADENOCARCINOMA : A HISTOCHEMICAL STUDY

CD15 and CEA expression in thymic epithelial neoplasms

3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project

Endosalpingiosis. Case report

Enterprise Interest None

The Diagnostic Utility of Immunohistochemistry in Undifferentiated Ovarian Carcinoma

Atypical Hyperplasia/EIN

Ovarian carcinoma classification. Robert A. Soslow, MD

The relative frequency and histopathological patterns of ovarian lesions: study of 116 cases

Histological Typing Of Cancer And Precancer Of The Oral Mucosa

A Useful Antibody Panel for Differential Diagnosis Between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

Page # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases:

LESION AT PACIFIC MEDICAL COLLEGE, UDAIPUR. 1. Assistant Professor, Department of Pathology, Pacific Medical college and hospital, Udaipur.

BSD 2015 Case 19. Female 21. Nodule on forehead. The best diagnosis is:

Case Report Ovarian mucinous cystic tumor with sarcoma-like mural nodules and multifocal anaplastic carcinoma: a case report

Histology: Its Influence on Therapeutic Decision Making

A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.

Case 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno

SALPINGITIS IN OVARIAN ENDOMETRIOSIS

p16ink4a expression in cervical intraepithelial neoplasia and cervical cancer

Institute of Pathology First Faculty of Medicine Charles University. Ovary

Papillary Lesions of the breast

of 20 to 80 and subsequently declines [2].

uterine cancer endometrial cancer

57th Annual HSCP Spring Symposium 4/16/2016

Role of Her-2 Neu As Prognostic Indicator in Surface Epithelial Tumors of Ovary.

CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III)

New Developments in Immunohistochemistry for Gynecologic Pathology

Effusion Cytology: Diagnostic Challenges

E-cadherin and Cytokeratin Subtype Profiling in Effusion Cytology

Mu ath M.A. Rjoub Supervised by: Dr. Huda Zahawi, FRCPath. King Abdullah University Hospital )KAUH(

Case 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:

Papillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.

Current Concept in Ovarian Carcinoma: Pathology Perspectives

Craniopharyngiomas are epithelial neoplasms thought

Invited Re vie W. Molecular genetics of ovarian carcinomas. Histology and Histo pathology

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD

Wendy L Frankel. Chair and Distinguished Professor

Tissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2

Case Report Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report

Case 3 - GYN. History: 66 year old, routine Pap test. Dr. Stelow

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

Synchronous squamous cell carcinoma of the breast. and invasive lobular carcinoma

Histological Pattern of Ovarian Neoplasma

Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1

ROLE OF PROSTATIC BASAL CELL MARKER IN DIAGNOSIS OF PROSTATIC LESIONS

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

CODING TUMOUR MORPHOLOGY. Otto Visser

Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis

Immunohistochemical Profile of Lung Tumors in Image Guided Biopsies

Enterprise Interest Nothing to declare

Spectrum of Lesions in Cystoscopic Bladder Biopsies -A Histopathological Study

Biliary tract tumors

The PAX8 gene is a member of the paired-box family of

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

Romanian Journal of Morphology and Embryology 2006, 47(1):53 58

Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000

Disclosure of Relevant Financial Relationships

JMSCR Vol 05 Issue 11 Page November 2017

Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity

HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE PERIOD

Malignant transformation in benign cystic teratomas, dermoids of the ovary

Muco-epidermoid tumours of the anal canal

RECLASSIFICATION OF CA CERVIX USING MUCIN STAINS AND ITS CLINICAL RELEVANCE

Cytological evaluation of effusion fluid with cell block technique and cytology smears among Sudanese patients

Expression of Cytokeratins 7 and 20 in Ovarian Neoplasia

Transcription:

ISPUB.COM The Internet Journal of Pathology Volume 13 Number 2 Immunohistochemical Expression of Cytokeratin 5/6 in Gynaecological Tumors. A Baghla, S Choudhry, A Kataria Citation A Baghla, S Choudhry, A Kataria.. The Internet Journal of Pathology. 2012 Volume 13 Number 2. Abstract Gynecological malignancies are very common as they represent second most common cause of fatal cancer in women comprising 42.5% of all malignancies in women. Histopathological examination is helpful to a larger extent in diagnosis of all gynecological malignancies but has limitations in cases of undifferentiated malignancies and tumors showing heterogeneous composition. In such cases immunohistochemistry is strongly recommended. Various tumour markers applied for specific diagnosis are cytokeratin, vimention, carcinoembryonic antigen (CEA), Epithelial membrane antigen (EMA). Cytokeratin 5/6 being present in cervical epithelium show strong positivity for squamous cell carcinoma and hence preferred. Focal positivity of cytokeratin 5/6 is also seen in ovarian and endometrial adenocarcinoma in areas of squamous differentiation. In the present study expression of cytokeratin 5/6 positivity was evaluated in cervical, ovarian and endometrial carcinoma using primary antibody cytokeratin 5/6; clone D 5/16 B4 (M7237) (DAKO) in formalin fixed and paraffin embedded tissue sections. Results were be correlated with histological types and different grades. INTRODUCTION Neoplasms of the female genitalia represent the second most 1 common source of fatal cancer in women. Gynaecological malignancies comprise 42.5% of all malignancies in women.2 Carcinoma cervix is the most common malignant tumour found among Indian women constituting 80% of all gynaecological tumours.3 Ovarian and endometrial tumour 2 constitute 15% and 2% respectively. Generally gynaecological malignancies arises above the age of 35 years4 with endometrial carcinoma having predilection for elderly women.5 Histopathology, although has been helpful to a larger extent in differentiating the type of malignancy and identifying the tissue of origin but it has limited role in undifferentiated malignancies and tumors showing heterogeneous composition. To overcome that immunohistochemistry has a key role in diagnosing malignancies of uncertain origin. Much divergence is seen in differentiation of epithelium in various organs of female genital tract. Epithelial neoplasm arising from these organs show very heterogeneous and 6 pleomorphic composition. But during malignant transformation of epithelium, its keratin profile remains constant hence keratin expression is widely used in 7 fingerprinting of various carcinomas. Cytokeratin 5/6 is used as a marker of squamous differentiation and is helpful in assessing poorly differentiated squamous cell carcinoma as well as the squamous differentiation which occur in 20% endometrial 8 adenocarcinoma by its focal positivity. In addition, Cytokeratin 5/6 has a pivotal role to play in identifying metastatic carcinoma with squamous differentiation such as adenosquamous cell carcinoma of endometrium and ovary.9 AIMS AND OBJECTIVES To study the expression of cytokeratin 5/6 in various histological types and grades of carcinoma cervix, ovarian carcinoma and endometrial carcinoma. MATERIALS AND METHODS The study was conducted on 40 cases of gynaecological tumors which included 20 cases of cervical carcinoma, 10 cases of endometrial carcinoma and 10 cases of ovarian carcinoma. Tissues were processed routinely and stained with haematoxylin and eosin (H & E). Cytokeratin 5/6 immunohistochemical staining was done on 4 µm thick paraffin sections using the standard peroxidaseantiperoxidase method. All steps were carried out in a moist and humid chamber, so that the sections remain moist 1 of 7

throughout the procedure. Positive control was put up with every batch. The primary antibody used was Concentrated mouse monoclonal antihuman cytokeratin 5/6, clone D 5/16 B4 (M7237) (DAKO). Figure 2 Table II:Correlation of CK 5/6 score with different histological types and grades of cervical carcinomas. Cytokeratin 5/6 scoring was done according to the criteria laid down by Smedts et al (1992)10 and Ordonez (1998)11 in their respective studies on gynaecological malignancies. The scoring was based upon the percentage of CK 5/6 positive cells as score 1 is given when 1-25% of the tissue shows positivity, score 2 when 26-50% was positive, score 3 when 51-75% was positive and score 4 when 76-100% cells show positivity. RESULTS Of the forty cases of gynaecological malignancies, 20 were cervical carcinomas which were further differentiated into their histological types and the comparative CK 5/6 expression was studied. Grading was done based upon the criteria laid down by Kristensen B et al on the basis of degree of keratinization, nuclear pleomorphism, pattern of invasion and host response into grade I to grade IV. Table I shows cervical carcinomas statistics according to histological typing. It was observed that maximum no. of cases were histologically squamous cell carcinoma (large cell non-keratinizing type) and of grade III. Table II shows compiled view of all the cases and IHC scoring for all grades and types. Figure 1 Table I: Different histological types of cervical carcinomas. 2 of 7 Figure 3 Fig. 1- Strong ck5/6 immunostaining in SCC (large cell keratinizing type) grade I (10x)

Figure 4 Figure 6 Fig.2-Strong focal ck5/6 immunostaining in SCC (keratinizing type)grade I(10x) Fig.4. Weak ck5/6 immunostaining in squamous cell carcinoma with minimum keratinization grade 111 (10x) CK 5/6 IN ENDOMETRIAL CARCINOMA Figure 5 Fig.3-Moderate ck5/6 immunostaining in squamous cell carcinoma with minimum keratinization grade iii (10x) Out of the 10 cases of endometrial carcinomas, 6 cases (60%) were positive for CK 5/6. Here also histological typing and grading was done and CK 5/6 expression in all cases was done and results are depicted in table III and IV. Figure 7 Table 111: Correlation of CK 5/6 score with different histological types of endometrial carcinoma. Figure 8 Table IV:Correlation of CK5/6 score with histological grades of endometrial carcinoma. 3 of 7

Figure 9 CK 5/6 IN OVARIAN CARCINOMAS Fig.5-Weak ck 5/6 immunostaining in endometrial adenocarcinoma (40x) Four out of 10 cases (i.e. 40%) of ovarian carcinomas showed positivity for CK 5/6. Histological typing and grading and then staining with CK 5/6 revealed the results as shown in tables V and VI. Figure 12 Table V:Correlation of CK5/6 score with histological types of ovarian carcinomas. Figure 10 Fig.6-Moderate ck5/6 immunostaining in poorly differentiated endometrial adenocarcinoma grade 111 (10x) Figure 13 Fig.8- Moderate ck5/6 immunostaining in Papillary serous cyst adenocarcinoma (10x) Figure 11 Fig.7-Strong focal ck5/6 immunstaining in areas of squamous and columnar differentiation in endometrial adenocarcinoma with squamous metaplasia (10x) Figure 14 Table VI: Correlation of CK5/6 score with histological grades of ovarian carcinoma. DISCUSSION The heterogeneous and pleomorphic neoplasms of the female genital tract arising from the epithelia of multipotent coelomic origin are to be diagnosed with the help of immunomarkers like cytokeratin 5/6. CK 5/6 is a stratification marker and is normally present in stratified 4 of 7

epithelium, transitional epithelium and mesothelial cells12 7 and also in malignant transformation of these epithelia. All of the 20 cervical carcinomas were positive for CK 5/6 in which 19 were squamous cell carcinomas and only 1 was adenosquamous cell carcinoma. This was in congruence with 7 the studies conducted by Moll et al (1983) and Smedts et al (1992)10 who observed CK 5/6 positivity in all cases of squamous cell carcinoma. Thus, IHC scoring for CK 5/6 was very helpful in analysing large cell keratinizing type squamous cell carcinomas that scored the highest (5 out of 6 cases scored 4) as compared to large non keratinizing type (6 out of 11 cases scored 4) and adenosquamous carcinomas which were weakly positive. This weak expression of CK 5/6 by the glandular architecture in adenosquamous carcinoma cervix favours the fact that adenocarcinoma as well as squamous cell carcinoma of cervix are the part and parcel of the same spectrum but on the opposite ends arising from the common progenitor cells i.e. reserve cells of the transitional zone.10,13 Among the different grades, grade I showed high percentage of CK 5/6 cells with strong intensity as compared to grade IV. It can be assumed that undifferentiated cells possibly have lost its keratin and became larger cells and showed only focal positivity in areas of squamous differentiation. Out of the 10 cases of endometrial carcinomas, 6 were positive for CK 5/6. Four of these cases pure endometrial adenocarcinoma showed weak positivity for CK 5/6. But comparatively the poorly differentiated endometrial carcinomas showed increased CK 5/6 positivity. Chu et al 14 15 (2002) and Moll et el (1991) demonstrated that CK 5/6 expression in endometrial adenocarcinoma is focal, weak or not at all, which correlates completely with observation in the present study. Two cases out of six positive cases were having squamous metaplasia which showed greater CK 5/6 expression. Similarly Moll et al (1991)15 and Hans et al (2003)9 illustrated CK 5/6 expression in cases of endometrial adenocarcinoma with squamous metaplasia. All the cases were not only positive but also scored high. Taking into account, 4 positive cases of 10 ovarian carcinomas, Papillary serous cystadenocarcinomas presented with enhanced CK 5/6 expression in comparison to mucinous cystadenocarcinomas irrespective of their grades. This observation correlated completely with study done by 15 Moll et al (1991) on 6 cases of serous cystadenocarcinoma and 2 cases of mucinous cystadenocarcinoma ovary. Both the cases of mucinous cystadenocarcinoma ovary were 5 of 7 considered negative for CK5/6. But 5 out of 6 cases of papillary serous cystadenocarcinoma showed focal and irregular immunoreactivity for CK5/6 and scored 1. Ordonez (1998)11 studied CK5/6 immunoreactivity in 30 cases of ovarian carcinoma, out of which 10 were positive for CK 5/6. Eight out of these ten positive cases were serous cystadenocarcinoma ovary, among which 7 cases showed low percentage of CK5/6 positive tumour cells and hence scored 1. Only one case showed 30% of tumour cells positive for CK5/6 thus scored 2. CONCLUSION It is therefore concluded that Cytokeratin 5/6 is the diagnostic marker of squamous differentiation where histologically poorly differentiated or undifferentiated squamous cell carcinomas are concerned. The focal and weak positivity of CK 5/6 in carcinomas of female genital tract as compared to other adenocarcinoma like that of stomach, kidney, colon which are negative for CK5/6 could be a valuable aid in diagnostic dilemmas of metastasis. References 1. Friedrick TK. Female reproductive system. In: John M. Kissane, editor. Anderson s Pathology, 8th ed. Missouri: Anne & Patterson 1985; 141-1545. 2. Chabbra S, Sonak M, Prem V, Sharma S. Gynaecological malignancies in a rural institute in India. J Obstet Gynaecol 2002; 22 (4): 426-429. 3. Kumari S, Bhatia R, Aggarwal DS, Mitra AB, Luthra UK. Microbiology of female genital tract in cervical dysplasia and carcinoma. Indian J Med Res 1982; 75: 83-88 4. Roden RBS, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Human Pathology 2004; 35 (8): 971-982. 5. Lucas WE. Casual relationships between endocrine metabolic variables in patients with endometrial carcinoma. Obstet Gynecol Surv 1974; 29: 507-523. 6. Czernobilsky B.Primary epithelial tumors of the ovary. In: Blaustein A, editor. Pathology of female genital tract, 2nd ed.new York: Springer Verlag 1982; 511-540. 7. Moll R, Levy R, Czernobilsky B, Majert PH, Hellweg GD, Franke WW. Cytokeratins of normal epithelia and some neoplasms of female genital tract. Laboratory Investigation 1983; 49 (5): 599-610. 8. Yaziji H, Gowen A. Immunohistochemical analysis of gynecological tumors. International Journal of Gynecological Pathology 2001; 20 (1): 64-78. 9. Han J, Kim MK, Nam SJ, Yang JH. E-cadherin and cytokeratin subtype profiling in effusion cytology. J Korean Med Sci 2004; 19: 826-833. 10. Smedts F, Ramaekers F, Trovanousky S, Pruszczynski M, Link M, Lane B et al. Keratin expression in cervical cancer. American Journal of Pathology 1992; 141 (2): 497-511. 11. Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleural from

lung adenocarcinoma. The American Journal of Surgical Pathology 1998; 22 (10): 1215-1221. 12. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratin pattern of expression in normal epithelium, tumors and cultured cells. Cell 1982; 31: 11-24. 13. Smedts F, Ramaekers F, Vooijis P. The dynamics of keratin expression in malignant transformation of cervical epithelium: A review. Obstet Gynaecol 1993; 82 (3): 6 of 7 465-475. 14. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40: 403-439. 15. Moll R, Pitz S, Levy R, Weikel W, Franke WW, Chernobilsky B. Complexity of expression of intermediate filament proteins, including glial filament protein, in endometrial and ovarian adenocarcinoma. Hum Pathol 1991; 22: 981-1001.

Author Information Aditi Baghla Assistant Professor, Department of Pathology, Maharaja Agarsen Medical College Sakshi Choudhry Junior Resident, Government Medical College Amarjit Singh Kataria Professor and Head of Department, Government Medical College 7 of 7